natgillin/translations-raw huggingface dataset:
Following oral administration, approximately 5 % to 10 % of the dose is recovered unchanged in the urine over 24 hours, and the remainder excreted as temozolomide acid, 5-aminoimidazole-4- carboxamide (AIC) or unidentified polar metabolites.
Nakon peroralne primjene se približno 5 do 10 % doze nalazi u mokraći u nepromijenjenom obliku tijekom 24 sata, dok se ostatak izlučuje u obliku temozolomidske kiseline, 5-aminoimidazol-4-karboksamida ili neidentificiranih polarnih metabolita.
Following oral administration, approximately 5 % to 10 % of the dose is recovered unchanged in the urine over 24 hours, and the remainder excreted as temozolomide acid, 5-aminoimidazole-4- carboxamide (AIC) or unidentified polar metabolites.
Nakon peroralne primjene se približno 5 do 10% doze nalazi u mokraći u nepromijenjenom obliku tijekom 24 sata, dok se ostatak izlučuje u obliku temozolomidske kiseline, 5-aminoimidazol-4-karboksamida ili neidentificiranih polarnih metabolita.
Following oral administration, approximately 5% to 10% of the dose is recovered unchanged in the urine over 24 hours, and the remainder excreted as temozolomide acid, 5-aminoimidazole-4- carboxamide (AIC) or unidentified polar metabolites.
Nakon peroralne primjene se približno 5 do 10% doze nalazi u mokraći u nepromijenjenom obliku tijekom 24 sata, dok se ostatak izlučuje u obliku temozolomidske kiseline, 5-aminoimidazol-4-karboksamida ili neidentificiranih polarnih metabolita.
Following oral administration, approximately 5% to 10% of the dose is recovered unchanged in the urine over 24 hours, and the remainder excreted as temozolomide acid, 5-aminoimidazole-4-carboxamide (AIC) or unidentified polar metabolites.
Nakon peroralne primjene se približno 5 do 10% doze nalazi u mokraći u nepromijenjenom obliku tijekom 24 sata, dok se ostatak izlučuje u obliku temozolomidske kiseline, 5-aminoimidazol-4-karboksamida ili neidentificiranih polarnih metabolita.
Following oral administration, lamivudine was excreted in breast milk at similar concentrations to those found in serum.
Nakon peroralne primjene, lamivudin se izlučuje u majčino mlijeko u koncentracijama koje su slične onima pronađenima u serumu.
Following oral administration, naloxegol is absorbed rapidly, with peak concentrations (Cmax) achieved at less than 2 hours.
Naloksegol se nakon peroralne primjene brzo apsorbira, a vršne koncentracije (Cmax) postižu se za manje od 2 sata.
Following oral administration, palonosetron is well absorbed with its absolute bioavailability reaching 97 %.
Nakon oralne primjene palonosetron se dobro apsorbira uz svoju apsolutnu bioraspoloživost koja doseže 97%.
Following oral administration, the elimination half-life of tenofovir is approximately 12 - 18 hours.
Nakon peroralne primjene, poluvijek eliminacije tenofovira iznosi približno 12 do 18 sati.
Following oral administration, the increase in the mean exposure (AUC) is approximately proportional to the dose increment across doses ranging from 25 mg to 120 mg twice daily.
Nakon peroralne primjene, povećanje prosječne izloženosti (AUC) otprilike je proporcionalno povećanju doze u doznom rasponu od 25 mg do 120 mg dvaput dnevno.
Following oral administration, the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion.
Nakon peroralne primjene, veći dio ivakaftora (87,8%) eliminirao se stolicom nakon metaboličke konverzije.
Following oral administration, the mean time (tmax) to maximal serum concentrations (Cmax) is about an hour.
Nakon oralne primjene, srednje vrijeme (tmax) do postizanja maksimalne koncentracije u serumu (Cmax) je oko jedan sat.
Following oral and intravenous administration, levofloxacin is eliminated relatively slowly from the plasma (t1/2 6 to 8 hours).
Nakon peroralne i intravenske primjene levofloksacin se relativno sporo eliminira iz plazme (t1/2 6 do 8 sati).
Following oral dosing of 14C-olaparib to female patients, unchanged olaparib accounted for the majority of the circulating radioactivity in plasma (70%) and was the major component found in both urine and faeces (15% and 6% of the dose respectively).
Nakon peroralne primjene 14C-olapariba bolesnicama, olaparib je u neizmijenjenu obliku činio glavninu cirkulirajuće radioaktivnosti u plazmi (70%) te je bio glavna komponentna pronađena i u mokraći (15% doze) i u fecesu (6% doze).
Following oral dosing with 600 mg BID, steady-state was reached by approximately four weeks, with mean steady state plasma concentrations approximately 2,200 ng/ml.
Nakon peroralne primjene 600 mg dvaput na dan stanje dinamičke ravnoteže postiže se nakon približno 4 tjedna, uz prosječnu koncentraciju u plazmi u stanju dinamičke ravnoteže od oko 2200 ng/ml.
Following oral or intravenous administration of 14C irbesartan, 80-85 % of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Nakon peroralne ili intravenske primjene 14C irbesartana, 80-85% cirkulirajuće radioaktivnosti u plazmi odnosi se na nepromijenjeni irbesartan.
Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Nakon oralne ili intravenske primjene 14C irbesartana, 80-85% cirkulirajuće radioaktivnosti u plazmi odnosi se na nepromijenjeni irbesartan.
Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Nakon peroralne ili intravenske primjene 14C irbesartana 80-85% cirkulirajuće radiokativnosti u plazmi odnosi se na nepromijenjeni irbesartan.
Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Nakon peroralne ili intravenske primjene 14C irbesartana, 80-85% cirkulirajuće radiaoktivnosti u plazmi odnosi se na nepromijenjeni irbesartan.
Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Nakon peroralne ili intravenske primjene 14C irbesartana, 80-85% cirkulirajuće radiokativnosti u plazmi odnosi se na nepromijenjeni irbesartan.
Following oromucosal administration of Effentora, fentanyl is readily absorbed with an absolute bioavailability of 65%.
Nakon primjene Effentore kroz usnu sluznicu, fentanil se odmah apsorbira apsolutnom bioraspoloživošću od 65%.
Following passage into the systemic circulation, ziconotide is expected to be primarily susceptible to proteolytic cleavage by various ubiquitous peptidases/proteases present in most organs (e.g., kidney, liver, lung, muscle, etc.), and thus degraded to peptide fragments and its individual constituent free amino acids.
Nakon ulaza u sistemsku cirkulaciju, očekuje se da da će zikonotid biti prvenstveno osjetljiv na proteolitičko cijepanje od strane različitih ubikvitarnih peptidaza/proteaza prisutnih u većini organa (npr. bubreg, jetra, pluća, mišići itd.) pa stoga razgrađen na fragmente peptida i njihove sastavne pojedinačne slobodne aminokiseline.
Following pemetrexed plus cisplatin induction (4 cycles), treatment with pemetrexed was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio = 0.78, 95%CI = 0.64-0.96, p = 0.0195).
Nakon uvodnog liječenja pemetreksedom i cisplatinom (4 ciklusa), liječenje pemetreksedom bilo je statistički značajno bolje od placeba s obzirom na ukupno preživljenje (medijan 13,9 mjeseci naspram 11,0 mjeseci, omjer hazarda= 0,78; 95%CI = 0,64-0,96, p = 0,0195).
Following pemetrexed plus cisplatin induction (4 cycles), treatment with pemetrexed was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio = 0.78, 95%CI=0.64-0.96, p=0.0195).
Nakon uvodnog liječenja pemetreksedom i cisplatinom (4 ciklusa), liječenje pemetreksedom bilo je statistički značajno bolje od placeba s obzirom na ukupno preživljenje (medijan 13,9 mjeseci naspram 11,0 mjeseci, omjer hazarda= 0,78, 95% CI = 0,64-0,96, p = 0,0195).
Following pemetrexed plus cisplatin induction (4 cycles), treatment with pemetrexed was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio=0.78, 95 %CI=0.64- 0.96, p=0.0195).
Nakon uvodnog liječenja lijekom pemetreksed i cisplatinom (4 ciklusa), liječenje lijekom pemetreksed bilo je statistički značajno bolje od placeba s obzirom na OS (medijan 13,9 mjeseci naspram 11,0 mjeseci, omjer hazarda = 0,78, 95% CI = 0,64-0,96, p = 0,0195).
Following prior treatment with interferon (pegylated or non-pegylated), with or without ribavirin (see section 5.1).
Nakon prethodnog liječenja s interferonom (pregiliranim ili nepegiliranim), sa ili bez ribavirina (vidjeti dio 5.1)
Following randomization, 32 patients received deferoxamine (43.4 mg/kg/day for 5 days/week) and Ferriprox (75 mg/kg/day) and 33 patients received deferoxamine monotherapy (34.9 mg/kg/day for 5 days/week).
Nakon randomizacije, 32 bolesnika primala su deferoksamin (43,4 mg/kg/dan tijekom 5 dana u tjednu) i Ferriprox (75 mg/kg/dan), a 33 bolesnika primala su monoterapiju deferoksaminom (34,9 mg/kg/dan tijekom
Following recent enquiries from pharmacists and prescribers received in the past months regarding prescribing and dispensing restrictions for women of childbearing potential (WCBP), it came to the PRAC’s attention that the current warning in the Erivedge SmPC is not clear.
Nakon nedavnih upita koji su u posljednjih nekoliko mjeseci zaprimljeni od ljekarnika i liječnika propisivača u svezi s ograničenjima za propisivanje i izdavanje lijeka ženama reproduktivne dobi, PRAC-u je skrenuta pozornost na činjenicu da trenutno upozorenje u Sažetku opisa svojstava lijeka za Erivedge nije jasno.
Following reconstitution the oral suspension has a concentration of 20 mg per ml.
Nakon pripreme za primjenu, koncentracija oralne suspenzije iznosi 20 mg/ml.
Following reconstitution the oral suspension has a concentration of 20 mg per ml.
Nakon rekonstitucije, koncentracija oralne suspenzije iznosi 20 mg/ml.
Following reconstitution the product should be administered separately and not mixed with infusion solutions nor be given in a drip.
Nakon rekonstitucije, lijek se mora primijeniti odvojeno, a ne pomiješan s infuzijskim otopinama ili primijenjen u dripu.
Following reconstitution with the solvent (water for injections) the vial contains 1.0 ml of solution.
Nakon rekonstitucije s otapalom (vodom za injekcije) bočica sadrži 1,0 ml otopine.
Following reconstitution, the vaccine is a clear, colourless to light yellow solution, free from visible foreign particles.
Nakon rekonstitucije cjepivo je bistra, bezbojna do svijetložuta otopina bez vidljivih stranih čestica.
Following recovery to Grade 1 diarrhoea, resume ONIVYDE at a reduced dose (see section 4.2).
Nakon oporavka na proljev stupnja 1, treba nastaviti primjenu lijeka ONIVYDE u smanjenoj dozi (vidjeti dio 4.2).
Following reintroduction of pazopanib, if transaminase elevations > 3 x ULN recur, then pazopanib should be permanently discontinued.
Ako nakon ponovnog uvođenja pazopaniba ponovno dođe do porasta transaminaza na >3 x GGN, treba trajno prekinuti liječenje pazopanibom.
Following repeat dosing of fluticasone furoate/vilanterol for 7 days, there was an increase in fluticasone furoate systemic exposure (up to three-fold as measured by AUC(0–24)) in subjects with hepatic impairment (Child-Pugh A, B or C) compared with healthy subjects.
Nakon primjene ponovljenih doza flutikazonfuroata/vilanterola tijekom 7 dana, došlo je do povećanja sistemske izloženosti flutikazonfuroatu (do tri puta prema vrijednosti AUC(0–24)) u ispitanika s oštećenjem jetrene funkcije (Child-Pugh stadij A, B ili C) u odnosu na zdrave ispitanike.
Following repeat dosing of orally inhaled fluticasone furoate/vilanterol for 7 days, there was an increase in fluticasone furoate systemic exposure (on average two-fold as measured by AUC(0–24)) in subjects with moderate or severe hepatic impairment (Child-Pugh B or C) compared with healthy subjects.
Nakon ponavljanog doziranja oralno inhalirane kombinacije flutikazonfuroat/vilanterol tijekom 7 dana, došlo je do povećanja sistemske izloženosti flutikazonfuroatu (u prosjeku dvostruko prema mjerenju AUC(0–24)) u ispitanika s umjerenim ili teškim oštećenjem jetre (Child-Pugh B ili C) u usporedbi sa zdravim ispitanicima.
Following repeat subcutaneous administration of 140 mg every 2 weeks, the 12 week trough concentrations were 147% higher and 70% lower in patients of 69 kg and 93 kg respectively, than that of the typical 81 kg subject.
Nakon opetovane supkutane primjene doze od 140 mg svaka 2 tjedna, najniže koncentracije u 12. tjednu bile su 147% više odnosno 70% niže u bolesnika od 69 kg odnosno 93 kg, u odnosu na one u ispitanika uobičajene težine od 81 kg.
Following repeated administration at short intervals, the intensity and frequency of these reactions may be increased.
Nakon ponovljenih primjena u kratkim intervalima moguće je da će reakcije biti pojačanog intenziteta.
Following repeated administration, follitropin alfa accumulates 3-fold achieving a steady-state within 3-4 days.
Nakon ponovljenog davanja folitropin alfa nakuplja se trostruko , a njegova se ravnotežna razinai postiže nakon 3-4 dana.
Following repeated administration, follitropin alfa accumulates 3-fold achieving a steadystate within 3-4 days.
Nakon ponovljenog davanja, folitropin alfa nakuplja se trostruko, a stanje dinamičke ravnoteže postiže se nakon 3 do 4 dana.
Following repeated dosing of eliglustat 84 mg twice daily, steady state was reached by 4 days, with an accumulation ratio of 3-fold or less.
Nakon ponovljenog doziranja eliglustata od 84 mg dva puta dnevno, stanje dinamičke ravnoteže dosegnuto je za 4 dana, s omjerom nakupljanja od 3 puta ili manje.
Following repeated subcutaneous administration of peginterferon beta-1a in rhesus monkeys at doses up to 400-fold (based on exposure, AUC) the recommended therapeutic dose; no effects other than the known mild pharmacological responses by rhesus monkeys to interferon beta-1a were observed after the first and second weekly dose.
Nakon ponovljene supkutane primjene peginterferona beta-1a u rhesus majmuna u dozama do 400 puta (na temelju izloženosti, AUC) većima od preporučene terapijske doze; nije bilo drugih učinka osim poznatih blagih farmakoloških odgovora rhesus majmuna na interferon beta-1a opaženih poslije prve i druge tjedne doze.
Following resolution of transaminase elevations, the benefits and risks of resuming Kalydeco dosing should be considered.
Nakon što se povišene transaminaze snize, treba razmotriti koristi i rizike nastavka primjene lijeka Kalydeco.
Following routine haematological monitoring, the transdermal patch should only be applied to patients whose chemotherapy treatment is unlikely to be delayed in order to reduce the possibility of unnecessary exposure to granisetron.
Uzimajući u obzir rezultate rutinskih hematoloških ispitivanja, transdermalni flaster primjenjuje se samo u bolesnika u kojih se ne očekuje odgađanje kemoterapije, čime se smanjuje mogućnost nepotrebne izloženosti granisetronu.
Following routine signal activities, the MAH identified a new signal of application site scarring as part of this periodic safety update report.
Nakon kumulativnog pregleda zabilježeni su slučajevi koji čvrsto upućuju na preosjetljivost na ingenol mebutat (ingenoli mebutas), uključujući slučajeve sa značajkama angioedema.
Following SANCUSO application, granisetron is absorbed slowly, with maximal concentrations reached between 24 and 48 hours.
Nakon primjene transdermalnog flastera SANCUSO, granisetron se sporo apsorbira, a maksimalne koncentracije se dosežu nakon 24 do 48 sati.
Following SC administration, bioavailability was 62%.
Nakon supkutane primjene, bioraspoloživost je iznosila 62%.
Following short term treatment (median duration 47 days), weight gain ≥ 7 % of baseline body weight was very common (22.2%), ≥ 15% was common (4.2%) and ≥25% was uncommon (0.8%).
Nakon kratkotrajnog liječenja (medijan trajanja 47 dana) povećanje tjelesne težine ≥ 7 % od početne tjelesne težine bilo je vrlo često (22,2 %), povećanje ≥ 15 % bilo je često (4,2 %), a ≥ 25 % bilo je manje često (0,8 %).
Following short term treatment (median duration 47 days), weight gain ≥ 7 % of baseline body weight was very common (22.2%), ≥ 15% was common (4.2%) and ≥25% was uncommon (0.8%).
Nakon kratkotrajnog liječenja (medijan trajanja 47 dana), povećanje tjelesne težine ≥ 7 % od početne tjelesne težine bilo je vrlo često (22,2 %), povećanje ≥ 15 % bilo je često (4,2 %), a ≥ 25 % bilo je manje često (0,8 %).
Following single dose administration of 1.5 g of mycophenolate mofetil to normal healthy subjects pre-treated with 4 g TID of cholestyramine for 4 days, there was a 40% reduction in the AUC of MPA (see section 4.4 and section 5.2).
Nakon primjene jedne doze od 1,5 g mofetilmikofenolata u normalnih zdravih osoba koje su prethodno liječene dozom od 4 g kolestiramina triput dnevno tijekom četiri dana, došlo je do smanjenja AUC-a (površina ispod krivulje) MPA za 40% (vidjeti dijelove 4.4 i 5.2).
Following single dose administration of 100 mg Betmiga in volunteers with mild hepatic impairment (Child-Pugh Class A), mean mirabegron Cmax and AUC were increased by 9% and 19% relative to volunteers with normal hepatic function.
Nakon primjene pojedinačne doze od 100 mg lijeka Betmiga u dobrovoljaca s blagim oštećenjem jetre (Child-Pugh stadij A), srednja vrijednost Cmax i AUC mirabegrona povećana je za 9% odnosno 19%, u usporedbi s dobrovoljcima s normalnom funkcijom jetre.
Following single dose Combivir administration in healthy volunteers, mean (CV) lamivudine and zidovudine Cmax values were 1.6 µg/ml (32%) and 2.0 µg/ml (40%), respectively and the corresponding values for AUC were 6.1 µg h/ml (20%) and 2.4 µg h/ml (29%) respectively.
Nakon primjene jedne doze Combivira zdravim dobrovoljcima, srednje (CV) vrijednosti Cmax lamivudina iznosile su 1,6 μg/ml (32%), a zidovudina 2,0 μg/ml (40%), a odgovarajuće vrijednosti AUC bile su 6,1 μg h/ml (20%), odnosno 2,4 μg h/ml (29%).
Following single dose intravenous infusion of Aloxi 20 µg/kg, peak plasma concentrations (CT) reported at the end of the 15 minute infusion were highly variable in all age groups and tended to be lower in patients < 6 years than in older paediatric patients.
Nakon jednokratne intravenske infuzije Aloxija u dozi od 20 µg/kg, vršne koncentracije u plazmi (CT) zabilježene na kraju 15-minutne infuzije bile su visoko varijabilne u svim dobnim skupinama i u bolesnika u dobi <6 godina kretale su se u nižim vrijednostima nego u starijih pedijatrijskih bolesnika.
Following single dose lamivudine/zidovudine administration in healthy volunteers, mean (CV) lamivudine and zidovudine Cmax values were 1.6 µg/ml (32 %) and 2.0 µg/ml (40 %), respectively and the corresponding values for AUC were 6.1 µg h/ml (20 %) and 2.4 µg h/ml (29 %) respectively.
Nakon primjene jedne doze lamivudina/zidovudina zdravim dobrovoljcima, srednje (CV) vrijednosti Cmax lamivudina iznosile su 1,6 μg/ml (32%), a zidovudina 2,0 μg/ml (40%), a odgovarajuće vrijednosti AUC bile su 6,1 μg h/ml (20%), odnosno 2,4 μg h/ml (29%).
Following single dose, oral administration of 1.5 g of mycophenolate mofetil to normal healthy subjects pre-treated with 4 g TID of cholestyramine for 4 days, there was a 40% reduction in the AUC of MPA (see section 4.4, and section 5.2).
Nakon oralne primjene jedne doze od 1,5 g mofetilmikofenolata u normalnih zdravih osoba koje su prethodno liječene dozom od 4 g kolestiramina triput dnevno tijekom četiri dana, došlo je do smanjenja AUC-a (površina ispod krivulje) MPA za 40% (vidjeti dijelove 4.4 i 5.2).
Following single doses of [cyano-14C] isavuconazonium and [pyridinylmethyl-14C] isavuconazonium sulfate in humans, in addition to the active moiety (isavuconazole) and the inactive cleavage product, a number of minor metabolites were identified.
Nakon jednokratnih doza [cijano-14C] izavukonazonija i [piridinilmetil-14C] izavukonazonijeva sulfata kod ljudi, osim aktivnog oblika (izavukonazola) i inaktivnog produkta razgradnje, utvrĎeni su brojni sekundarni metaboliti.
Following single oral administration of 14C-labeled Sivextro under fasted conditions, the majority of elimination occurred via the liver with 81.5% of the radioactive dose recovered in faeces and 18% in urine, with most of the elimination (>85%) occurring within 96 hours.
Nakon jednokratne peroralne primjene radioaktivno obilježenog (14C) lijeka Sivextro natašte, veći dio se eliminirao putem jetre, s 81,5% radioaktivne doze pronađene u stolici i 18% u urinu, a veći dio eliminacije (>85%) odvio se unutar 96 sati.
Following single oral administration of [14C] fingolimod, the major fingolimod-related components in blood, as judged from their contribution to the AUC up to 34 days post dose of total radiolabelled components, are fingolimod itself (23%), fingolimod phosphate (10%), and inactive metabolites (M3 carboxylic acid metabolite (8%), M29 ceramide metabolite (9%) and M30 ceramide metabolite (7%)).
Nakon jednokratne peroralne primjene [14C] fingolimoda, glavne komponente u krvi povezane s fingolimodom, procijenjene prema njihovom doprinosu AUC-u do 34 dana nakon doze ukupnih radiooznačenih komponenti, sam su fingolimod (23%), fingolimodfosfat (10%) i inaktivni metaboliti (M3 metabolit karboksilne kiseline (8%), M29 ceramidni metabolit (9%) i M30 ceramidni metabolit (7%)).
Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours.
Nakon primjene jedne oralne doze (20 mg/kg) u djece s epilepsijom (6 do 12 godina), poluvijek levetiracetama bilo je 6,0 sati.
Following single oral doses of ceritinib, the geometric mean apparent plasma terminal half-life (T½) of ceritinib ranged from 31 to 41 hours in patients over the 400 to 750 mg dose range.
Nakon jednokratnih peroralnih doza ceritiniba, geometrijska srednja vrijednost prividnog terminalnog poluvijeka ceritiniba u plazmi (T½) bila je u rasponu od 31 do 41 sata u bolesnika koji su primali doze u rasponu od 400 do 750 mg.
Following single oral doses of  300 mg, peak plasma concentrations appear to plateau, possibly due to saturation of absorption.
Nakon jedne oralne doze od  300 mg, čini se da vršna koncentracija plazme postiže plato, vjerojatno radi saturacije apsorpcije.
Following single oral doses of  300 mg, peak plasma concentrations appear to plateau, possibly due to saturation of absorption.
Čini se da nakon jednokratnih oralnih doza od  300 mg, vršna plazmatska koncentracija dosiže plato, moguće zbog saturacije apsorpcije.
Following single-dose administration of posaconazole oral suspension, there was no effect of mild and moderate renal impairment (n=18, Cl cr ≥ 20 mL/min/1.73 m2) on posaconazole pharmacokinetics; therefore, no dose adjustment is required.
Nakon primjene jednokratne doze posakonazol oralne suspenzije, blago ili umjereno oštećenje funkcije bubrega (n=18, CIcr ≥20 ml/min/1,73 m2) nije utjecalo na farmakokinetiku posakonazola, pa nije potrebna prilagodba doze.
Following single-dose oral administration of 14C–daclatasvir in healthy subjects, 88% of total radioactivity was recovered in feces (53% as unchanged drug) and 6.6% was excreted in the urine (primarily as unchanged drug).
Nakon peroralne primjene jednokratne doze 14C–daklatazvira u zdravih ispitanika, 88% ukupne radioaktivnosti otkriveno je u fecesu (53% u neizmijenjenu obliku), a 6,6% izlučeno je kroz mokraću (prvenstveno u neizmijenjenu obliku).
Following subcutaneous administration of 2.25 µg/kg to adult cancer patients a mean peak concentration of 10.6 ng/ml (SD 5.9) of darbepoetin alfa was reached at a mean time of 91 hours (SD 19.7).
Nakon supkutane primjene 2,25μg/kg odraslim bolesnicima s rakom, postignuta je srednja vrijednost vršne koncentracije od 10,6 ng/ml (SD 5,9) u srednjem vremenu od 91 sat (SD 19,7).